Skip to content
Tuesday, March 28
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Sports
  • Press Release
The Prime Media

The Prime Media

Just another WordPress site

The Prime Media

The Prime Media

Just another WordPress site

  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Sports
  • Press Release
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Sports
  • Press Release
Trending Now
  • ICA Italian Wood Finishes – Good Taste Shows.
  • National CSR Network Hosts Successful Workshop on Social Return on Investment
  • Vaastu Mahaguru Basannt R Rasiwasia receives the coveted MEGA Foundation Award for ReVaastu
  • The much awaited theater play “7:40 ki Ladies Special” was sensational at its debut. The play was presented by renowned film maker Mr Mahesh Bhatt and produced by Mr Sandip Kapur
  • Charting New Paths: Eligarapu Chandrasekhar expands his entrepreneurship in the Overseas Career Guidance in Helping Students to Reach Their Full Potential with Fuera Global Services
  • Gaurav Shetty Aces at Redefining Hospitality Management
Home>>Press Release>>TB Alliance committed to accessibility of TB therapy in India
Press Release

TB Alliance committed to accessibility of TB therapy in India

The Prime India Online Desk
March 24, 2022

The DCGI (Drug Controller General of India) approved TB drug, pretomanid, for conditional access under the National Tuberculosis Elimination Program (NTEP), can play a significant role towards elimination of highly drug-resistant TB in India 

Pretomanid is a ‘made in India’ product used as part of a six-month treatment regimen with reported efficacy of 90%; has potential to contribute to India’s ‘TB Elimination program by 2025’ 

New Delhi, India March 24: The world continues to battle against pandemics, including COVID-19 and tuberculosis (TB). March 24, marks World TB Day and TB Alliance, a global not-for-profit organization, is joining with partners around the globe to raise awareness of one of the world’s oldest diseases. TB had been the world’s leading infectious killeruntil COVID-19. This new pandemic has shown that new tools, diagnostics, drugs, and vaccines can be quickly developed and deployed with the adequate funding and political will. The same resources are needed to bring the TB pandemic under control and make progress toward a TB-free world.

In July 2020, the Drug Controller General of India (DCGI) had approved the TB drug pretomanid (developed specifically for certain drug-resistant forms of the disease) for conditional access under the National Tuberculosis Elimination Program (NTEP), making India the second country in the world to provide regulatory approval for this product.

On the occasion of World TB Day, Sandeep Juneja, Sr. VP, Market Access at TB Alliance, said“New regimens are urgently needed to treat this deadly infectious disease, especially drug-resistant forms of TB which have a history of poor cure rates and treatments with often intolerable side effects. We welcome the fact that more than 30 countries, including India, have obtained pretomanid-based regimens to treat highly drug-resistant forms of TB.TB Alliancestands ready to work side by side and learn from India and every other country seeking to implementnew TB therapies. Our job is not done until each treatment we develop is accessible to every person who needs it.”

A government-led study of the regimen in India called *mBPaL commenced in October 2021 and is now enrolling patients at three sites out of a planned 11. It is scheduled to reach its primary completion in 2023 after enrolling 400 patients.

TB Alliance manages the largest portfolio of TB drug candidates, with more than 30 projects under active development. Its researchers and research partners are working to advance the development of new TB compounds and medicines, with a goal to develop a short, simple, and affordable TB regimens suitable for all people with TB.

To date, 17 countries or regulatory bodies, including India, have approved pretomanid as part of the BPaL regimen for the treatment of patients with highly drug-resistant forms of TB. Regulatory applications have been submitted to another 13 countries and counting by Viatris, TB Alliance’s global commercialization partner for pretomanid as part of the regimen. Viatris is joined by Macleods, Lupin, and Hongqi Pharma in holding licenses for pretomanid in countries with high TB burdens.

Data from TB Alliance’s ZeNix trial of the BPaL regimen, presented in 2021, demonstrated improvement in the safety and tolerability of the BPaL regimen with alterations in linezolid dosing with sustained favorable outcomes in 89 precent of all participants.

Though important advances have been made in recent years, the need to invest in TB research and development is even more apparent amidst the COVID-19 pandemic, which has already reversed hard-won progress against TB. In 2020, the world saw the first increase in TB deaths since 2005, and a 15 percent reduction in the number of people treated for drug-resistant TB.

Bringing the TB pandemic under control can only be realized through global commitment and collaboration. TB Alliance is committed to contributing to this aspiration by inventing novel therapies that radically reshape the treatment landscape and save lives.

*BPaL regimen combines the antibiotics bedaquiline (B), pretomanid (Pa) and linezolid (L)

Related tags : PNN

Previous Post

Dr. Vivek Mansingh Teams Up With Practically To Deliver an Insightful Masterclass on Achieving Success and Growth

Next Post

International Chief of Brahma Kumari Dadi Ratan Mohini felicitated President Awardee Dr Sohini Sastri

Related Articles

Press Release

Sohan S Das releases new book Armnesia, a story of an Amnesiac Soldier

Press Release

Designer Karishma Deepa Sondhi launches her new collection “Summer Sorbets“ With a 2 Day Exhibition at her Flagship Store

Press Release

Kushal and Sharmistha’s Roxy Music to promote budding singers from across the country

Press Release

Why the world needs spiritual leader like Raseshwari Devi Ji?

Press Release

The Indian Heritage Fashion Show 2022

Recent Posts

  • ICA Italian Wood Finishes – Good Taste Shows.
  • National CSR Network Hosts Successful Workshop on Social Return on Investment
  • Vaastu Mahaguru Basannt R Rasiwasia receives the coveted MEGA Foundation Award for ReVaastu
  • The much awaited theater play “7:40 ki Ladies Special” was sensational at its debut. The play was presented by renowned film maker Mr Mahesh Bhatt and produced by Mr Sandip Kapur
  • Charting New Paths: Eligarapu Chandrasekhar expands his entrepreneurship in the Overseas Career Guidance in Helping Students to Reach Their Full Potential with Fuera Global Services

Recent Comments

    © 2023 The Prime Media | WordPress Theme Ultra News
    • Business
    • Entertainment
    • National
    • Lifestyle
    • Education
    • Sports
    • Press Release